These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1954343)

  • 1. Immunotoxins containing ricin or its A chain.
    Vitetta ES; Thorpe PE
    Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
    Neville DM
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxin therapy of cancer.
    Frankel AE
    Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of immunotoxins.
    Cobb PW; LeMaistre CF
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ricin--a plant toxin with potential therapeutic use].
    Nagy M
    Ceska Slov Farm; 2004 May; 53(3):131-4. PubMed ID: 15218734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions.
    Vitetta ES
    Princess Takamatsu Symp; 1988; 19():333-40. PubMed ID: 3077626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
    [No Abstract]   [Full Text] [Related]  

  • 13. Potentiation of TNF-alpha toxicity by conjugation with ricin A-chain.
    Gould DJ; Foxwell BM; Feldmann M; Chernajovsky Y
    Cytokine; 1998 Dec; 10(12):931-9. PubMed ID: 10049516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
    Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
    Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
    J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
    Vallera DA; Uckun FM
    Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.